KR20230024977A - 심방 기능 부전의 치료 - Google Patents

심방 기능 부전의 치료 Download PDF

Info

Publication number
KR20230024977A
KR20230024977A KR1020237001177A KR20237001177A KR20230024977A KR 20230024977 A KR20230024977 A KR 20230024977A KR 1020237001177 A KR1020237001177 A KR 1020237001177A KR 20237001177 A KR20237001177 A KR 20237001177A KR 20230024977 A KR20230024977 A KR 20230024977A
Authority
KR
South Korea
Prior art keywords
patient
compound
atrial
optionally
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237001177A
Other languages
English (en)
Korean (ko)
Inventor
장-프랑수아 탐비
제이 엠. 에델버그
그레고리 하워드 타케오 쿠리오
신시아 라일 켈리
천 양
마르쿠스 패트릭 헨제
카를로스 엘. 델 리오
로버트 리 앤더슨
마리우스 피. 수만데아
지텐드라 간주
Original Assignee
미요카디아, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미요카디아, 인크. filed Critical 미요카디아, 인크.
Publication of KR20230024977A publication Critical patent/KR20230024977A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
KR1020237001177A 2020-06-15 2021-06-14 심방 기능 부전의 치료 Pending KR20230024977A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US63/039,438 2020-06-15
US202063042512P 2020-06-22 2020-06-22
US63/042,512 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Publications (1)

Publication Number Publication Date
KR20230024977A true KR20230024977A (ko) 2023-02-21

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237001177A Pending KR20230024977A (ko) 2020-06-15 2021-06-14 심방 기능 부전의 치료

Country Status (13)

Country Link
US (1) US20230233545A1 (https=)
EP (1) EP4164644A1 (https=)
JP (2) JP7832128B2 (https=)
KR (1) KR20230024977A (https=)
CN (1) CN116056703A (https=)
AU (1) AU2021293817A1 (https=)
BR (1) BR112022025551A2 (https=)
CA (1) CA3180943A1 (https=)
CL (1) CL2022003548A1 (https=)
IL (1) IL298885A (https=)
MX (1) MX2022015488A (https=)
TW (1) TW202214241A (https=)
WO (1) WO2021257456A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN117379683B (zh) * 2023-12-12 2024-02-27 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234017B1 (en) * 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
AU2018266199A1 (en) * 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
DK3645002T3 (da) * 2017-06-30 2024-12-16 Amgen Inc Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer
KR20220009440A (ko) * 2019-05-19 2022-01-24 미요카디아, 인크. 화합물 (r)-4-(1-((3-(디플루오로메틸)-1-메틸-1h-피라졸-4-일)술포닐)-1-플루오로에틸)-n-(이속사졸-3-일)피페리딘-1-카르복스아미드를 사용한 수축기 기능장애 및 감소된 박출 계수를 가진 심부전의 치료

Also Published As

Publication number Publication date
EP4164644A1 (en) 2023-04-19
JP7832128B2 (ja) 2026-03-17
BR112022025551A2 (pt) 2023-03-07
US20230233545A1 (en) 2023-07-27
TW202214241A (zh) 2022-04-16
MX2022015488A (es) 2023-03-21
CA3180943A1 (en) 2021-12-23
JP2023529502A (ja) 2023-07-10
WO2021257456A1 (en) 2021-12-23
IL298885A (en) 2023-02-01
CL2022003548A1 (es) 2023-06-09
CN116056703A (zh) 2023-05-02
JP2026048841A (ja) 2026-03-17
AU2021293817A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
JP7832128B2 (ja) 心房機能不全の治療
TWI874399B (zh) 心縮功能障礙之治療
JP7830321B2 (ja) ミオシンモジュレーターによる治療方法
JP4870888B2 (ja) 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用
JP2023540485A (ja) ミオシンモジュレーターによる治療方法
RU2384346C2 (ru) Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
RU2362561C2 (ru) Фармацевтическая композиция, включающая селективный агонист имидазолинового рецептора i1 и блокатор рецептора ангиотензина ii
HK40091633A (zh) 心房功能障碍的治疗
US20250325531A1 (en) Treatment of systolic dysfunction
US12616697B2 (en) Methods of treatment with myosin modulator
HK40061292A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
HK40077232A (en) Methods of treatment with myosin modulator
US20070185065A1 (en) Combination therapy for coronary artery disease
HK1096293B (en) Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000